A multiple-dose, phase Ib study of KL-1333 in healthy volunteers and genetic mitochondrial disease patients
Phase of Trial: Phase I
Latest Information Update: 21 May 2018
At a glance
- Drugs KL 1333 (Primary)
- Indications Mitochondrial disorders
- Focus Adverse reactions
- Sponsors NeuroVive Pharmaceutical
- 21 May 2018 Results published in the Media Release
- 21 May 2018 According to a NeuroVive Pharmaceuticals media release, results of this study are expected in the first half of 2019.
- 18 Apr 2018 According to a NeuroVive Pharmaceuticals media release, the company expects to start this trial in second half of 2018.